591 | NOVEL CHEMOTHERAPY‐FREE INITIAL TREATMENT OF RITUXIMAB PLUS PEGYLATED INTERFERON Α‐2B IN UNTREATED ADVANCED INDOLENT B‐CELL LYMPHOMA: 4‐YEAR FOLLOW‐UP STUDY

作者：G. Yan, Lu Ping, Jiani Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fengyuan Li, Xi Li, Xuguang Wang, Bin Bai, Huijiao Chen, He Huang, Yi He, He Huang · 发表于：Hematological Oncology · 年份：2025 · DOI：10.1002/hon.70096_591 · 被引用次数：1 · 研究领域：Lymphoma Diagnosis and Treatment、Chronic Lymphocytic Leukemia Research、Immune Cell Function and Interaction

G. Yan and L. Ping equally contributing author. Background: Indolent B-cell lymphomas (iBCL), accounting for 10%–15% of non-Hodgkin lymphoma (NHL) subtypes in China, exhibit clinical heterogeneity. While generally associated with favorable survival, most iBCL cases remain incurable. Rituximab monotherapy demonstrates efficacy in initial treatment, and preclinical studies suggest interferon-alpha (IFN-α) may synergistically enhance rituximab activity through immune modulation. Pegylated IFN-α2 (Peg-IFN-α2) offers improved pharmacokinetics with reduced toxicity compared to conventional IFN-α and is utilized in chronic hepatitis B (CHB) management. The phase II RIPPLE trial (NCT04246359) evaluates rituximab biosimilar combined with Peg-IFN-α2b in treatment-naïve iBCL. Methods: Newly diagnosed iBCL (follicular lymphoma [FL] grades 1–2/3a, marginal zone lymphoma [MZL], lymphoplasmacytic lymphoma [LPL], small lymphocytic lymphoma [SLL]); ECOG ≤ 2; adequate organ function; measurable disease. Patients with chronic hepatitis B co-infection (HBsAg+, HBV DNA < 3000 IU/mL, ALT < 5 × ULN) were permitted for enrollment. Induction therapy consisted of rituximab biosimilar (Henliritux; 375 mg/m2 IV day 1) plus Peg-IFN-α2b (Pegberon; 135μg SC days 1, 8) every 21 days for 6 cycles. Responders received maintenance (rituximab every 8 weeks; Peg-IFN-α2b monthly) for ≤ 2 years. CHB patients received entecavir prophylaxis. Primary endpoint: investigator-assessed ORR and CR (Lugano 2014). Secondary...